AGIO - Agios Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
79.20
+0.85 (+1.08%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close78.35
Open74.83
Bid0.00 x 0
Ask0.00 x 0
Day's Range74.52 - 80.10
52 Week Range39.24 - 80.10
Volume1,574,868
Avg. Volume542,217
Market Cap3.861B
Beta2.00
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Celgene's Investments Are Soaring
    Motley Fool21 hours ago

    Celgene's Investments Are Soaring

    The biotech Goliath's investment portfolio is paying off.

  • Reuters5 days ago

    Agios sizes up funding needs

    Jan 19 - Agios Pharmaceuticals pivoted from industry conferences to the capital markets, securing US$425m in a follow-on stock sale that meets its funding needs for the year. JP Morgan, Goldman Sachs and ...

  • Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year
    Zacks5 days ago

    Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year

    Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.

  • See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

    Short interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding AGIO totaled $1.71 billion.

  • Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 81 RS Rating
    Investor's Business Daily13 days ago

    Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 81 RS Rating

    A Relative Strength Rating upgrade for Agios Pharmaceuticals shows improving technical performance.

  • How Did Bioverativ Perform in 3Q17?
    Market Realist13 days ago

    How Did Bioverativ Perform in 3Q17?

    A Snapshot of Bioverativ's Recent Performance

  • Analysts’ Recommendations for Bioverativ in January 2018
    Market Realist14 days ago

    Analysts’ Recommendations for Bioverativ in January 2018

    A Snapshot of Bioverativ's Recent PerformanceRecent developments

  • See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

    Agios Pharmaceuticals Inc NASDAQ/NGS:AGIO

  • Market Realist20 days ago

    How Analysts Rated Jazz Pharmaceuticals in December

    In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

  • Capital Cube26 days ago

    ETFs with exposure to Agios Pharmaceuticals, Inc. : December 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.
    Zacks28 days ago

    Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.

    Agios (AGIO) submits new drug application to the FDA for ivosidenib for relapsed or refractory acute myeloid leukemia and IDH1 mutation. The company has also filed request for a priority review.

  • Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo
    Zacks28 days ago

    Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo

    A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.

  • American City Business Journals29 days ago

    Agios lines up another potential FDA nod with new leukemia drug

    Less than five months after getting its first cancer drug approved, Cambridge-based Agios Pharmaceuticals has lined up another potential FDA nod — and the first for a medicine that it fully owns. Agios (AGIO) said Tuesday that it had submitted an application for ivosidenib, a potential drug for patients with acute myeloid leukemia who have a specific genetic mutation, and whose cancer has relapsed or isn’t responding to initial treatment. The company said it had asked the FDA to review the application within six months, rather than the usual 10.

  • Reuterslast month

    Promising responses seen with Agios leukemia drug in study

    Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday. The study tested Agios' ivosidenib, a once-a-day pill, in patients with an IDH1 gene mutation who had relapsed or were not helped by prior treatment for acute myeloid leukemia (AML). Of 125 patients available for evaluation in the expansion of a Phase I study, 30.4 percent experienced a complete response or a complete response with partial hematologic recovery (CRh), researchers reported.

  • American City Business Journalslast month

    Cambridge biotechs among big winners at ASH blood disease conference

    A handful of local biotechs were among the major headliners this weekend at the American Society of Hematology’s annual blood disease conference in Atlanta. During the ASH conference, which runs through Tuesday, companies from across the country gather to unveil new data from trials of their drugs for blood cancer and other diseases, with investors keeping close tabs on the presentations. bluebird bio (BLUE): bluebird made perhaps the biggest splash in Atlanta this weekend, announcing Sunday that a cancer drug it’s developing with Celgene Corp. had performed exceptionally well in a Phase 1 trial.

  • IBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Relative Price Strength
    Investor's Business Daily2 months ago

    IBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Relative Price Strength

    A Relative Strength Rating upgrade for Agios Pharmaceuticals shows improving technical performance. Will it continue?

  • Capital Cube2 months ago

    ETFs with exposure to Agios Pharmaceuticals, Inc. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • The Wall Street Journal2 months ago

    [$$] VC Focus: Once Rare, Health-Care Megarounds Grow More Common

    More medical startups are stocking up with massive inflows of venture capital.

  • Forbes2 months ago

    Fighting Cancer One Patient At A Time

    Companies large and small are competing to attack rare genetic mutations that cause cancer. The reason? Great science and high drug prices. The result? Soaring stock prices.

  • Agios Posts New Data on Glioma Candidate from Dose Expansion
    Zacks2 months ago

    Agios Posts New Data on Glioma Candidate from Dose Expansion

    Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.

  • Capital Cube2 months ago

    ETFs with exposure to Agios Pharmaceuticals, Inc. : November 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 9, 2017
    Capital Cube2 months ago

    Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 9, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Agios Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Agios Pharmaceuticals, Inc. : November 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
    Capital Cube3 months ago

    Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017

    Categories: Yahoo FinanceGet free summary analysis Agios Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Agios Pharmaceuticals, Inc. – Exelixis, Inc., Pfizer Inc., Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Celgene Corporation, GlaxoSmithKline plc Sponsored ADR and BioMarin Pharmaceutical Inc. (EXEL-US, PFE-US, LLY-US, ... Read more (Read more...)

  • Agios targeting cancer medicines
    CNBC Videoslast month

    Agios targeting cancer medicines

    CNBC's Meg Tirrell speaks with Agios CEO David Schenkein about how the company is zeroing in on cancerous and noncancerous blood diseases.